DANVERS, Mass.--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD) today announced it recently received a written response from the U.S. Food and Drug Administration (FDA) related to the Company’s submission for 510(k) clearance of its Impella 2.5 circulatory support device.
